Search the Newsreel

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. announced that its Compensation Committee granted equity inducement awards to five new employees. These awards, issued on August 13, 2026, consist of stock options to purchase up to 16,000 shares of common stock at an exercise price of $88.88 per share, …

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Goldman Sachs initiated coverage on Onto Innovation with a Buy rating and a $400 price target, leading a list of five new analyst initiations. Other companies receiving new coverage include Columbia Financial, Target Hospitality, Dave Inc, and Pulse Biosciences, all with bullish ratings and …

Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com

This article reports that Lexaria Bioscience Corp. filed a Form 8K on August 17. The filing is an important regulatory disclosure for investors and the market. The article is from Investing.com and was published on August 17, 2026, at 17:46.

Burcon NutraScience Stock Under Pressure: Can Commercialization Momentum Withstand the Latest Correction?

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Gilead Sciences has successfully transformed its business, moving past stagnant growth from declining hepatitis C and COVID-19 drug sales to robust expansion driven by new HIV and oncology therapies. The company reported double-digit revenue growth in Q2, with strong sales from HIV drugs like …

Vigonvita Life Sciences Schedules Board Meeting to Approve Interim Results and Dividend

Kingfa Science & Technology authorizes KMPs for Reg 30 disclosures

34,701 Shares in Gilead Sciences, Inc. $GILD Purchased by Occidental Asset Management LLC

Occidental Asset Management LLC has purchased 34,701 shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, valued at approximately $4.4 million. Other institutional investors also increased their holdings, with institutional ownership now at 83.67%. Gilead reported strong Q2 results with revenue exceeding expectations …

Solara Active Pharma Sciences Ltd. Share Price Today Up

Jade Biosciences Company Profile & Introduction

This document is intended to be a company profile and introduction for Jade Biosciences. The content is currently empty, suggesting it will provide foundational information about the company.

Ensysce Biosciences (ENSC) director buys stock and converts debt

Ensysce Biosciences director Bob G. Gower reported significant insider transactions, including two open-market purchases of common stock and the conversion of senior convertible promissory notes. These transactions resulted in Gower acquiring a total of 908,614 shares and establishing a warrant position, reflecting a positive …

Mitsubishi UFJ Asset Management Co. Ltd. Buys New Holdings in Boston Scientific Corporation $BSX

Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake in Boston Scientific Corporation (NYSE:BSX), purchasing over 3.6 million shares valued at approximately $154.4 million. This move is part of broader institutional investment activity, with other hedge funds also adjusting their positions in …

OneDigital Investment Advisors LLC Takes $1.27 Million Position in Edwards Lifesciences Corporation $EW

OneDigital Investment Advisors LLC has acquired a new position of 14,060 shares, valued at $1.27 million, in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter. This move is part of broader institutional interest, with hedge funds and other institutional investors owning 79.46% of the …

Plato Investment Management Ltd Takes Position in Ciena Corporation $CIEN

Plato Investment Management Ltd acquired 4,355 shares of Ciena Corporation (NYSE:CIEN) valued at approximately $2.1 million in the second quarter. Other institutional investors also increased their holdings in the company, bringing institutional ownership to 91.99%. Ciena reported strong quarterly earnings and revenue, beating analyst …

Trivium Point Advisory LLC Takes $4.15 Million Position in Thermo Fisher Scientific Inc. $TMO

Trivium Point Advisory LLC has initiated a new $4.15 million position in Thermo Fisher Scientific Inc. by purchasing 8,277 shares. Institutional investors collectively own a significant 89.23% of the company's stock. Analysts maintain a "Moderate Buy" consensus rating with an average price target of …

SCS Capital Management LLC Acquires Shares of 1,711 Thermo Fisher Scientific Inc. $TMO

SCS Capital Management LLC recently acquired 1,711 shares of Thermo Fisher Scientific Inc., valued at approximately $859,000, initiating a new position in the medical research company. Institutional investors and hedge funds collectively own 89.23% of the company, and analysts maintain a "Moderate Buy" rating …

Transtech Optelecom Sets Board Meeting to Review Interim Results and Dividend Plan

InnoScience Schedules Board Meeting to Approve Interim Results and Consider Dividend

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has received an average "Moderate Buy" rating from twelve brokerages, with nine analysts recommending a buy and one a strong buy, resulting in an average 12-month price target of $35.14. Despite the positive analyst outlook, company insiders sold over 2 …

Old West Investment Management LLC Invests $5.05 Million in Thermo Fisher Scientific Inc. $TMO

Old West Investment Management LLC has acquired a new stake worth approximately $5.05 million in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter. Institutional investors now own 89.23% of the company, which maintains a "Moderate Buy" consensus rating from analysts with an average …

Conway Capital Management Inc. Takes $1.23 Million Position in Boston Scientific Corporation $BSX

Conway Capital Management Inc. has initiated a new position in Boston Scientific Corporation (NYSE:BSX), purchasing 28,750 shares valued at approximately $1.23 million, making it their 25th biggest position. Other institutional investors have also adjusted their holdings in BSX. The company currently holds a "Moderate …

Anatara Lifesciences Narrows Annual Loss but Faces Going-Concern Warning

Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD

Grandfield & Dodd LLC recently acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, purchasing 154,287 shares valued at approximately $19.5 million. This investment comes alongside other institutional interest in Gilead Sciences, while some Wall Street analysts have adjusted their …

HBK Sorce Advisory LLC Buys Shares of 7,047 Thermo Fisher Scientific Inc. $TMO

HBK Sorce Advisory LLC recently purchased 7,047 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $4.07 million during the second quarter. Other institutional investors have also adjusted their holdings in the medical research company, which currently has a market capitalization of $216.90 …

German American Bancorp Inc. Takes $4.92 Million Position in Thermo Fisher Scientific Inc. $TMO

Family Legacy Inc. Invests $1.39 Million in Thermo Fisher Scientific Inc. $TMO

Family Legacy Inc. recently acquired a new stake in Thermo Fisher Scientific Inc., purchasing 2,766 shares valued at approximately $1.39 million. This investment is part of a broader trend of institutional and hedge fund activity in TMO stock. The article also details recent analyst …

8,148 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Global Retirement Partners LLC

Global Retirement Partners LLC recently acquired a new position in Thermo Fisher Scientific Inc., purchasing 8,148 shares valued at approximately $4.085 million during the second quarter. This move is part of broader institutional investor activity, with several other hedge funds also adjusting their holdings …

GSA Capital Partners LLP Takes Position in Gilead Sciences, Inc. $GILD

GSA Capital Partners LLP has acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, purchasing 9,877 shares valued at approximately $1.248 million. The article also details other institutional investor activity, insider selling by Gilead's CFO and CEO, and recent analyst …

Indogulf Cropsciences shares Q1FY27 earnings call recording

Avalon Trust Co Buys Shares of 35,466 Thermo Fisher Scientific Inc. $TMO

Avalon Trust Co recently acquired 35,466 shares of Thermo Fisher Scientific Inc., valued at approximately $17.78 million, making it their 27th largest holding. Other institutional investors have also adjusted their positions in the medical research company. Additionally, two company executives, Lisa P. Britt and …

121,844,108 Shares in Gilead Sciences, Inc. $GILD Purchased by BlackRock Inc.

BlackRock Inc. has acquired 121.8 million shares of Gilead Sciences (NASDAQ:GILD) worth approximately $15.4 billion, establishing a 9.81% stake in the biopharmaceutical company. This significant purchase contributes to institutional investors and hedge funds collectively owning 83.67% of the company's stock. Analysts maintain a "Moderate …

1ST Source Bank Takes Position in Thermo Fisher Scientific Inc. $TMO

1ST Source Bank has acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO), purchasing 16,133 shares valued at approximately $8.088 million in the second quarter. This move is part of broader institutional investment trends, with other firms also increasing their holdings in the …

Alberta Investment Management Corp Invests $9.83 Million in Thermo Fisher Scientific Inc. $TMO

Alberta Investment Management Corp recently acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 19,600 shares valued at approximately $9.83 million in the second quarter. Other institutional investors have also adjusted their holdings in the medical research company, which currently has …

XRF Scientific Slides to a 52-Week Low as Investors Wait on FY26 Results

Guggenheim lowers Spruce Biosciences stock price target to $104

Guggenheim has reduced its price target for Spruce Biosciences (NASDAQ: SPRB) to $104 from $123, while maintaining a Buy rating. The company is preparing for a global confirmatory study for its biologics license application and expanding its commercial leadership team ahead of potential FDA …

Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade

Alto Neuroscience (NYSE:ANRO) recently hit a new 52-week high after HC Wainwright increased its price target from $50 to $55, maintaining a "buy" rating. The company's stock has a "Moderate Buy" consensus from analysts and an average price target of $37.25. Institutional investors have …